نتائج البحث - "Benjamin Drogat"

المساهمون: Actions for OnCogenesis understanding and Target Identification in ONcology (ACTION), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Molecular Oncology Program, Spanish National Cancer Research Center (CNIO), Centre National de la Recherche Scientifique (CNRS), Translational Research Laboratory, Catalan Institute of Oncology, Catalan Institute of Oncology [Barcelone, Espagne], School of Life Science and Technology, Tongji University, Laboratory of Experimental Pathology, GIGA-Cancer, Groupe Interdisciplinaire de Génoprotéomique Appliqué-Cancer (GIGA-Cancer), Department of Medical Oncology, Catalan Institute of Oncology, Clinical Research in Solid Tumors (CReST) Group, Oncobell Program, IDIBELL, L'Hospitalet, Barcelona, Spain, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER-Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Turcq, Beatrice

المصدر: JCI Insight
JCI Insight, American Society for Clinical Investigation, 2020, 5 (15), ⟨10.1172/jci.insight.137869⟩
Dipòsit Digital de la UB
Universidad de Barcelona
JCI Insight, 2020, 5 (15), ⟨10.1172/jci.insight.137869⟩

مصطلحات موضوعية: 0301 basic medicine, Takeda Oncology, Lung Neoplasms, Molecular biology, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Voronoi, Apoptosis, Mirati Therapeutics, Novartis, and LOXO Oncology, medicine.disease_cause, Mice, 0302 clinical medicine, Araxes Pharma, Cell Movement, Antineoplastic Combined Chemotherapy Protocols, Quimioteràpia, Tumor Cells, Cultured, SFJ Pharmaceuticals, Boehringer Ingelheim, has sponsored research agreements with AstraZeneca, General Medicine, 3. Good health, [SDV] Life Sciences [q-bio], Gene Expression Regulation, Neoplastic, ACEA Biosciences, Oncology, 030220 oncology & carcinogenesis, receives postmarketing royalties from DFCI-owned intellectual property on EGFR mutations licensed to Lab Corp, Ignyta, Adenocarcinoma, Female, KRAS, Drug therapy, Lung cancer, Research Article, Paclitaxel, Sanofi Oncology, and Company, Context (language use), Adenocarcinoma of Lung, Therapeutics, Biocartis, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Discoidin Domain Receptor 1, In vivo, PUMA, medicine, Biomarkers, Tumor, Animals, Humans, Chemotherapy, and Takeda Oncology, Cell Proliferation, DDR1, business.industry, Astellas Pharmaceuticals, and has stock ownership in Gatekeeper Pharmaceuticals and LOXO Oncology, Eli Lilly and Company, medicine.disease, Xenograft Model Antitumor Assays, Revolution Medicines, Daiichi-Sankyo, 030104 developmental biology, Tumor progression, Drug Resistance, Neoplasm, Mutation, Cancer research, Càncer de pulmó, Cisplatin, business